Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Payables (2023 - 2025)

CG Oncology (CGON) has disclosed Payables for 3 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 12.32% year-over-year to $5.7 million, compared with a TTM value of $5.7 million through Dec 2025, down 12.32%, and an annual FY2025 reading of $5.7 million, down 12.32% over the prior year.
  • Payables was $5.7 million for Q4 2025 at CG Oncology, down from $9.2 million in the prior quarter.
  • Across five years, Payables topped out at $9.2 million in Q3 2025 and bottomed at $3.2 million in Q4 2023.
  • Average Payables over 3 years is $5.7 million, with a median of $5.7 million recorded in 2025.
  • Peak annual rise in Payables hit 125.54% in 2025, while the deepest fall reached 12.32% in 2025.
  • Year by year, Payables stood at $3.2 million in 2023, then soared by 101.02% to $6.5 million in 2024, then decreased by 12.32% to $5.7 million in 2025.
  • Business Quant data shows Payables for CGON at $5.7 million in Q4 2025, $9.2 million in Q3 2025, and $7.1 million in Q2 2025.